Search research articles
Contact Us
Filters
Showing results (81-90 of 129) with videos related to
Page
of 13
Sort By:
Cancer Discovery
|
May 16, 2024
A Functional Survey of the Regulatory Landscape of Estrogen Receptor-Positive Breast Cancer Evolution
Iros Barozzi, Neil Slaven, Eleonora Canale, et al.
Plos Genetics
|
January 3, 2023
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)
Lorenzo Ferrando, Andrea Vingiani, Anna Garuti, et al.
ACS Nanoscience Au
|
October 20, 2025
Delivery of Biomolecules into Individual Cells and Subcellular Compartments by Localized Electroporation via Nanopipette
Fabio Marcuccio, Philip S Goff, Devkee M Vadukul, et al.
Nature Genetics
|
May 27, 2017
Corrigendum: Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer
Luca Magnani, Gianmaria Frigè, Raffaella Maria Gadaleta, et al.
Nature Communications
|
December 9, 2025
Chemically modified CRISPR-Cas9 enables targeting of individual G-quadruplex and i-motif structures, revealing ligand-dependent transcriptional perturbation
Sabrina Pia Nuccio, Enrico Cadoni, Roxani Nikoloudaki, et al.
Cytokine & Growth Factor Reviews
|
February 21, 2021
Anticancer innovative therapy congress: Highlights from the 10th anniversary edition
Francesca De Santis, Giovanni Fucà, Dirk Schadendorf, et al.
Nature Communications
|
August 21, 2019
Author Correction: SREBP1 drives keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer
Ylenia Perone, Aaron J Farrugia, Alba Rodríguez-Meira, et al.
Nature Communications
|
April 23, 2020
Exploiting evolutionary steering to induce collateral drug sensitivity in cancer
Ahmet Acar, Daniel Nichol, Javier Fernandez-Mateos, et al.
Nature Communications
|
May 11, 2019
SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer
Ylenia Perone, Aaron J Farrugia, Alba Rodríguez-Meira, et al.
Biorxiv : the Preprint Server for Biology
|
August 8, 2025
Chemically modified CRISPR-Cas9 enables targeting of individual G-quadruplex and i-motif structures, revealing ligand-dependent transcriptional perturbation
Sabrina Pia Nuccio, Enrico Cadoni, Roxani Nikoloudaki, et al.
Page
of 13
Search research articles
Search
Showing results (81-90 of 129) with videos related to
Sort By:
Page
of 13
Cancer Discovery
|
May 16, 2024
A Functional Survey of the Regulatory Landscape of Estrogen Receptor-Positive Breast Cancer Evolution
Iros Barozzi, Neil Slaven, Eleonora Canale, et al.
Plos Genetics
|
January 3, 2023
ESR1 gene amplification and MAP3K mutations are selected during adjuvant endocrine therapies in relapsing Hormone Receptor-positive, HER2-negative breast cancer (HR+ HER2- BC)
Lorenzo Ferrando, Andrea Vingiani, Anna Garuti, et al.
ACS Nanoscience Au
|
October 20, 2025
Delivery of Biomolecules into Individual Cells and Subcellular Compartments by Localized Electroporation via Nanopipette
Fabio Marcuccio, Philip S Goff, Devkee M Vadukul, et al.
Nature Genetics
|
May 27, 2017
Corrigendum: Acquired CYP19A1 amplification is an early specific mechanism of aromatase inhibitor resistance in ERα metastatic breast cancer
Luca Magnani, Gianmaria Frigè, Raffaella Maria Gadaleta, et al.
Nature Communications
|
December 9, 2025
Chemically modified CRISPR-Cas9 enables targeting of individual G-quadruplex and i-motif structures, revealing ligand-dependent transcriptional perturbation
Sabrina Pia Nuccio, Enrico Cadoni, Roxani Nikoloudaki, et al.
Cytokine & Growth Factor Reviews
|
February 21, 2021
Anticancer innovative therapy congress: Highlights from the 10th anniversary edition
Francesca De Santis, Giovanni Fucà, Dirk Schadendorf, et al.
Nature Communications
|
August 21, 2019
Author Correction: SREBP1 drives keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer
Ylenia Perone, Aaron J Farrugia, Alba Rodríguez-Meira, et al.
Nature Communications
|
April 23, 2020
Exploiting evolutionary steering to induce collateral drug sensitivity in cancer
Ahmet Acar, Daniel Nichol, Javier Fernandez-Mateos, et al.
Nature Communications
|
May 11, 2019
SREBP1 drives Keratin-80-dependent cytoskeletal changes and invasive behavior in endocrine-resistant ERα breast cancer
Ylenia Perone, Aaron J Farrugia, Alba Rodríguez-Meira, et al.
Biorxiv : the Preprint Server for Biology
|
August 8, 2025
Chemically modified CRISPR-Cas9 enables targeting of individual G-quadruplex and i-motif structures, revealing ligand-dependent transcriptional perturbation
Sabrina Pia Nuccio, Enrico Cadoni, Roxani Nikoloudaki, et al.
Page
of 13